Nouscom today announced encouraging new translational data obtained from the ongoing Phase 1 trial evaluating NOUS-209. The data were presented yesterday in a Late Breaking session at the 2022 American Association for Cancer Research (AACR) Annual Meeting. NOUS-209, Nouscom’s lead product, is an off-the-shelf cancer vaccine targeting 209 shared neoantigens. It is being investigated in…

eTurboNews izindatshana ezababhalisi kuphela. Ukubhalisa kuyinto MAHHALA.
Ababhalisile bangena lapha Chofoza lapha ukuze ubhalise MAHHALA

LOKHO ONGAKUTHATHE KULESI SIHLOKO:

The data were presented yesterday in a Late Breaking session at the 2022 American Association for Cancer Research (AACR) Annual Meeting.
NOUS-209, Nouscom’s lead product, is an off-the-shelf cancer vaccine targeting 209 shared neoantigens.
eTurboNews izindatshana ezababhalisi kuphela.